Finzati - Logo
PTCT logo

PTC Therapeutics, Inc.

PTCT • Biotechnology
$0.00
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
HIGHLY FAVORABLE PROFILEExcellentConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$6.26B
Growth
8.5%
Cash Flow
1/5
Trend
Volatile
Evidence
Stable or improving margins · 39.4%Positive revenue growth · 29.9%Positive free cash flow · 8.83Reasonable earnings multiple · 8.85Healthy liquidity · 2.35
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.00
Change0.00%
Market Cap$6.26B
52W Range43.17 - 90.87
Beta0.53
Gross Margin95.85%
Oper. Margin49.49%
Profit Margin39.44%
Debt/Eq-2.40
Current Ratio2.35
Quick Ratio2.27
Revenue 5Y8.47%

Investment DNA

How strong this company looks for long-term investors

85
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
85/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
89/100
Why this score▼
Stable or improving margins · 39.4%Positive revenue growth · 29.9%Positive free cash flow · 8.83Reasonable earnings multiple · 8.85Healthy liquidity · 2.35

Analyst view

Analyst sentiment and price target

Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-07-31
Low
$85.00
Mean
$104.00
Median
$106.00
High
$130.00

Company Overview

IPO: 6/20/2013
Industry: Biotechnology
P/B i: -29.43
Debt / Equity i: -2.40
Operating Margin: 49.49%
Net Margin: 39.44%
ROE i: -
ROIC: -

Financial Health

Score17 / 20
Debt / Equity: -2.40
Current Ratio: 2.35
Quick Ratio: 2.27
Status: Strong

Insider Transactions

Recent executive and insider activity

Sollie-Zetlmayer Hege Elisabeth
Transaction: 07/28/2026
OTHER
Change
+11,250
Price
$39.42
Filing
07/30/2026
Type
OTHER
Sollie-Zetlmayer Hege Elisabeth
Transaction: 07/28/2026
OTHER
Change
0
Price
Not reported
Filing
07/30/2026
Type
OTHER
Gravier Pierre
Transaction: 07/14/2026
SELL
Change
-3,494
Price
$80.35
Filing
07/16/2026
Type
SELL